Ventilator associated pneumonia: unravelling prevalence risk factor and antibiotic usage
DOI:
https://doi.org/10.18203/2320-6012.ijrms20240213Keywords:
Hospital acquired infections, Ventilator associated pneumoniaAbstract
Background: Hospital acquired infections, are a leading cause of mortality and morbidity. Ventilator associated pneumonia, one of the hospital acquired illnesses. The purpose of this study was to evaluate the prevalence, risk factors, causative organism, and antibiotic usage for the treatment of ventilator-associated pneumonia.
Methods: Between May 2022 and October 2022, 50 patients participated in an ambispective and observational study conducted across several ICU departments at Adichunchanagiri Hospital, BG Nagara, Karnataka. Reviewing and evaluating daily patient case sheets, laboratory results, and treatment charts of participants who were hospital inpatients provided pertinent data needed for the study. Volunteers were enrolled after taking consent from each of them, a suitably designed data collection form was used to collect all the necessary information. Microsoft Excel was used to enter the data. Version 28 of SPSS was used to analyze the data. Statistical significance was determined by using a P-value of less than 0.05.
Results: The study included 50 patients and discovered a 60% prevalence of ventilator-associated pneumonia in the general community. Staphylococcus aureus accounted for 26.7% of all gram-positive bacteria, whereas Enterobacter and Klebsiella species accounted for 16.7%. Metronidazole was given in 64% of instances, with accidents being the most frequent risk factor (40%).
Conclusions: Within the specified population, the incidence of ventilator-associated pneumonia is 60%, with Staphylococcus aureus identified as the most predominant bacterial pathogen. Metronidazole is the most frequently prescribed antibiotic, and accidents are the key risk factors that cause ventilator-associated pneumonia.
Metrics
References
Hensley BJ, Monson JRT. Hospital-acquired infections. Surg (United Kingdom). 2015;33(11):528-33.
Park DR. The microbiology of ventilator-associated pneumonia. Respir Care. 2005;50(6):742-63.
Ranjan N, Chaudhary U, Chaudhry D, Ranjan KP. Ventilator-associated pneumonia in a tertiary care intensive care unit: Analysis of incidence, risk factors and mortality. Indian J Crit Care Med. 2014;18(4):200-4.
Chi SY, Kim TO, Park CW, Yu JY, Lee B, Lee S, et al. Bacterial pathogens of ventilator associated pneumonia in a tertiary referral hospital. Tuberc Respir Dis (Seoul). 2012;73(1):32-7.
Altinsoy S, Catalca S, Sayin MM, Tutuncu EE. The risk factors of ventilator associated pneumonia and relationship with type of tracheostomy. Trends Anaesth Crit Care. 2020;35(xxxx):38-43.
MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58(3):1359-64.
Pezhman B, Fatemeh R, Amir R, Mahboobeh R, Mohammad F. Nosocomial infections in an Iranian educational hospital: an evaluation study of the Iranian nosocomial infection surveillance system. BMC Infect Dis. 2021;21(1):1-8.
DiCocco JM, Croce MA. Ventilator-associated pneumonia: An overview. Expert Opin Pharmacother. 2009;10(9):1461-7.
Deshmukh B, Kadam S, Thirumugam M, Rajesh K. Clinical study of ventilator-associated pneumonia in tertiary care hospital, Kolhapur, Maharashtra, India. Int J Res Med Sci. 2017;5(5):2207.
Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med. 2004;32(6):1396-405.
Downloads
Published
How to Cite
Issue
Section
